Kuo P Y, Yen J T C, Parker G M, Chapman S, Kandikattu S, Sohanpal I, Barbachano Y, Williams J E
The Royal Marsden, NHS Foundation Trust, London SW3 6JJ, UK.
Sarcoma. 2011;2011:813483. doi: 10.1155/2011/813483. Epub 2011 May 5.
The prevalence of pain in patients with sarcoma is not well documented. We investigated this in outpatients at a tertiary cancer referral centre, assessing the adequacy of pain control and for risk factors leading to higher prevalence and severity of pain. 149 patients were surveyed. Patients with pain within the previous 7 days completed pain assessment tools (BPI, S-LANSS, PMI). 53% of patients had pain within the previous 7 days, and 25% had significant pain. Of those with pain, 63% was inadequately controlled and neuropathic pain was identified in 36%. Age, gender, tumour type, and the type of cancer treatment were not significant predictors of the prevalence or severity of the pain. Based on our results, patients with sarcoma should be actively screened for pain and have regular reviews of their analgesic requirements.
肉瘤患者疼痛的患病率尚无充分记录。我们在一家三级癌症转诊中心对门诊患者进行了调查，评估疼痛控制的充分性以及导致疼痛患病率和严重程度较高的风险因素。共对149名患者进行了调查。在过去7天内有疼痛的患者完成了疼痛评估工具（简明疼痛量表、利兹神经痛筛查工具、疼痛监测指数）。53%的患者在过去7天内有疼痛，25%的患者有严重疼痛。在有疼痛的患者中，63%的疼痛控制不充分，36%的患者被确定为神经性疼痛。年龄、性别、肿瘤类型和癌症治疗类型并非疼痛患病率或严重程度的显著预测因素。根据我们的研究结果，应对肉瘤患者进行积极的疼痛筛查，并定期评估其镇痛需求。
